论文部分内容阅读
目的：进行99mTc标记卵巢癌单抗放射免疫导向手术研究，为临床应用提供基础。方法：采用改进预锡法标记COC183B2-F(ab′)2和正常鼠IgG(NMIgG)，并分别向荷人卵巢癌裸鼠体内注入99mTc-COC183B２-F(ab′)2(单抗组)和99mTc-NMIgG(对照组)。首先在体外进行放射免疫显像(RII)初步决定探测时机，然后采用肿瘤探测仪(GDP)进行体内肿瘤及临近正常组织放射性测量，并计算肿瘤与非肿瘤放射性比值(T/NT)。结果：1改进预锡法单抗99mTc标记率达95%以上，标记后免疫组化染色显示标记物保留较好免疫活性；2GDP体内探测肿瘤最小为0.3cm×0.1cm，分辨瘤与正常组织间最小距离为0.2cm；T/NT(肝)为3.27±0.64、T/NT(脾)为2.23±0.47、T/NT(小肠)为3.33±0.84、T/NT(肌肉)为4.68±0.81，术中可以T/NT比值大于2为肿瘤阳性诊断标准；3RII和GDP体内探测显示，18h后可进行99mTc标记单抗片段放射免疫导向手术。结论：99mTc标记单抗进行卵巢癌放射免疫导向手术可行，有望用于临床。
OBJECTIVE: To study the radioimmunoassay of 99mTc-labeled ovarian cancer monoclonal antibody and provide the basis for clinical application. METHODS: COC183B2-F (ab ’) 2 and normal mouse IgG (NMIgG) were labeled by modified tin-plating method and 99mTc-COC183B2-F (ab’ And 99mTc-NMIgG (control group). Radioraimmunoimaging (RII) was initially performed in vitro to determine the timing of the initial detection. Radiological measurements of tumors in vivo and adjacent normal tissues were then performed using a tumor detector (GDP), and the tumor to non-tumor radioactivity ratio (T / NT) was calculated. The results showed that: 1Improved the 99mTc labeling rate of pre-tin method monoclonal antibody reached more than 95%, and the immunohistochemical staining showed that the marker retained better immunological activity after labeling; 2The minimal tumor detection of GDP was 0.3cm × 0.1cm, The minimum distance between normal tissues was 0.2 cm; T / NT (liver) was 3.27 ± 0.64; T / NT was 2.23 ± 0.47; T / NT was 3.33 ± 0.84; ± 0.81, intraoperative T / NT ratio greater than 2 for the diagnosis of tumor positive; 3 RII and GDP in vivo detection showed that 18h after radioimmunoassay 99mTc labeled monoclonal antibody. Conclusion: 99mTc-labeled mAb is feasible for radioimmunization of ovarian cancer and is expected to be used clinically.